Nektar CEO sells 20,000 shares in planned trade

Nektar Therapeutics President & CEO Howard W. Robin reported open-market sales of 20,000 shares of common stock over two days in mid-June 2026.

Filing Impact

(Very High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Nektar Therapeutics President & CEO Howard W. Robin reported open-market sales of 20,000 shares of common stock over two days in mid-June 2026. On June 16, 2026, he sold 5,303 shares at $59.97 and 4,697 shares at $60.71. On June 17, 2026, he sold 5,500 shares at $60.81 and 4,500 shares at $61.65. A footnote states that at least one transaction was made under a Rule 10b5-1 trading plan adopted on March 13, 2026, indicating the sales were pre-arranged. After these transactions, Robin directly owns 55,045 Nektar shares, and an additional 28 shares are held indirectly by his spouse.

Insider Trade Summary 10b5-1

Net Seller: 20,000 shares

Net Sell 5 txns

Insider ROBIN HOWARD W

Role President & CEO

Sold 20,000 shs ($1.22M)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,500	$60.81	$334K
Sale	Common Stock	4,500	$61.65	$277K
Sale	Common Stock	5,303	$59.97	$318K
Sale	Common Stock	4,697	$60.71	$285K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 55,045 shares (Direct); Common Stock — 28 shares (Indirect, by spouse)

Footnotes (5)

F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
F2. This transaction was executed in multiple trades at prices ranging from $59.35 to $60.33 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
F3. This transaction was executed in multiple trades at prices ranging from $60.37 to $61.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
F4. This transaction was executed in multiple trades at prices ranging from $60.22 to $61.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
F5. This transaction was executed in multiple trades at prices ranging from $61.22 to $62.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

Key Figures

Shares sold: 20,000 shares Sale price 1: $59.97/share Sale price 2: $60.71/share +5 more

8 metrics

Shares sold 20,000 shares Total common shares sold in open-market transactions in June 2026

Sale price 1 $59.97/share 5,303 shares sold on June 16, 2026

Sale price 2 $60.71/share 4,697 shares sold on June 16, 2026

Sale price 3 $60.81/share 5,500 shares sold on June 17, 2026

Sale price 4 $61.65/share 4,500 shares sold on June 17, 2026

Direct holdings after sales 55,045 shares Common stock directly owned by CEO after reported transactions

Indirect holdings 28 shares Common stock held indirectly by spouse as of June 16, 2026

Trade price ranges $59.35–$62.44 Price ranges for multiple trades underlying reported weighted average prices

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average sale price, indirect ownership, +1 more

5 terms

Rule 10b5-1 trading plan financial

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale; transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

indirect ownership financial

"total_shares_following_transaction: 28.0000, direct_or_indirect: I, nature_of_ownership: by spouse"

Form 4 regulatory

"INSIDER FILING DATA (Form 4): issuer Nektar Therapeutics, reporting person Howard W. Robin"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nektar Therapeutics (NKTR) report for its CEO?

Nektar Therapeutics reported that President & CEO Howard W. Robin sold 20,000 shares of common stock in open-market transactions. The sales occurred over two days in June 2026 at prices around the low-$60 range per share.

At what prices did Nektar CEO Howard W. Robin sell NKTR shares?

Howard W. Robin sold Nektar shares at reported prices of $59.97, $60.71, $60.81, and $61.65 per share. Footnotes note each was executed via multiple trades within price ranges roughly from $59.35 to $62.44 per share.

How many Nektar (NKTR) shares does the CEO hold after the reported sales?

After the reported open-market sales, CEO Howard W. Robin directly holds 55,045 shares of Nektar Therapeutics common stock. An additional 28 shares are reported as held indirectly through his spouse, according to the ownership details in the filing.

Were Nektar CEO Howard W. Robin’s NKTR stock sales under a Rule 10b5-1 plan?

Yes. A footnote explains that at least one of Howard W. Robin’s transactions was made under a Rule 10b5-1 trading plan adopted on March 13, 2026. Such plans pre-schedule trades, reducing the significance of timing decisions.

Over what dates did Nektar’s CEO sell the 20,000 NKTR shares?

The 20,000 Nektar Therapeutics shares were sold over two days, June 16 and June 17, 2026. Four separate open-market sale transactions were reported across those dates in the Form 4 insider trading disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 07:08 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBIN HOWARD W

(Last)

(First)

(Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO

CALIFORNIA

94158

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	06/16/2026		S		5,303	D	$59.97⁽²⁾	69,742	D
Common Stock⁽¹⁾	06/16/2026		S		4,697	D	$60.71⁽³⁾	65,045	D
Common Stock⁽¹⁾	06/17/2026		S		5,500	D	$60.81⁽⁴⁾	59,545	D
Common Stock⁽¹⁾	06/17/2026		S		4,500	D	$61.65⁽⁵⁾	55,045	D
Common Stock								28	I	by spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.

2. This transaction was executed in multiple trades at prices ranging from $59.35 to $60.33 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

3. This transaction was executed in multiple trades at prices ranging from $60.37 to $61.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

4. This transaction was executed in multiple trades at prices ranging from $60.22 to $61.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

5. This transaction was executed in multiple trades at prices ranging from $61.22 to $62.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

	Elizabeth Zhang, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR